The company’s innovations have not gone unnoticed. AI Medical Service was featured in 
SONIRE’s approach, which utilizes cavitation to enhance treatment accuracy, has been recognized by the U.S. FDA as a breakthrough device. The company is currently conducting a world-first randomized trial to further validate the efficacy of their technology. As CEO Satoh Tohru notes, the goal is to offer a more effective and safer cancer treatment to patients worldwide.
These Japanese startups are not only advancing medical technology but also providing hope for millions of cancer patients globally. As the world braces for a surge in cancer cases, innovations from companies like AI Medical Service and SONIRE Therapeutics could be pivotal in changing the landscape of cancer treatment.
Commercial Real Estate Deal Growth Stalls: What Slowing Momentum Means for 2026
Commercial real estate deal activity dipped in October for the first time since early 2024, signaling a widening disconnect between buyer and seller pricing expectations in a high‑rate environment. While overall sales remain strong—and even above 2024 levels—the sharp slowdown in momentum highlights rising caution across sectors. Multifamily saw a steep 27% drop in volume, hospitality was the lone sector to grow, and institutional buyers are increasingly targeting discounted office assets. With mortgage originations rebounding but lenders staying selective, 2026 will hinge on how quickly the market aligns on pricing and capital costs.
